Oral Cancer Vaccines
Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against oral cancer and guarantee the finest results for our customers all over the world.
Oral Cancer
Oral cancer is a type of head and neck cancer that grows in any cancerous tissue located in the mouth. There are several types of oral cancer, of which about 90% are squamous cell carcinomas that originate in the tissues of the mouth and lips. Oral cancer most commonly involves the tongue. It may also occur on the lips, cheek lining, floor of the mouth, gingiva (gums) or palate (the roof of the mouth). Early diagnosis of oral cancer patients will reduce mortality and help to improve treatment. The only sure way to determine the presence of cancer or precancerous cells is to assess the cells in the removed sample by biopsy and microscopy. If the tumor is small enough, surgical excision is usually recommended. Radiation therapy with or without chemotherapy is often used in conjunction with surgery or as a definitive radical cure, especially if the tumor is inoperable.
HPV Vaccines for Oral Cancer
Recent studies have shown a strong relationship between human papillomavirus (HPV) infection and head and neck cancer, especially oropharyngeal squamous cell carcinoma (OPSCC) and oral squamous cell carcinoma (OSCC). In 2011, the International Agency of Research of Cancer (IARC) announced that there is sufficient evidence that HPV-16 is associated with oral cancer. Moreover, the incidence of HPV-related OSCC appears to be on the rise while HPV-unrelated OSCC tends to have stabilized in the past decades. p16, a tumor suppressor gene, normally functions as a regulator of the cell cycle. Approximately 20-25% of OSCC are associated with HPV infection particularly HPV-16. p16 protein is a tumor suppressor, functioning as a cell cycle inhibitor. However, E7 protein in high-risk HPV subtypes can abrogate function of pRb protein resulting in aberrantly increased expression of p16 in HPV-related OSCC. Upon infection with high-risk types of HPV (HR-HPV), particularly types 16, 18, 31, 33, 34, 35, 39, 51, 52, 56, 58, 59, 66, 68, and 70, the expression of p16 is aberrantly overexpressed. Therefore, the expression of p16 is widely used as a surrogate marker for HPV infection in head and neck cancer.
Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the oral cancer vaccines. If you are interested in our services, please contact us for more details.
Reference
- Sritippho, T. (2015). “C Roles of Human Papillomaviruses and p16 in Oral Cancer.” Asian Pac J Cancer Prev 16(15), 6193-6200.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
